Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses RAPT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RAPT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian Wong | $630,000 | $0 | $0 | $5,927,297 | $416,000 | $0 | $6,242 | $6,979,539 |
| President and Chief Executive Officer | ||||||||
| Rodney Young | 478,000 | 0 | 0 | 1,975,492 | 229,440 | 0 | 8,564 | 2,691,496 |
| Chief Financial Officer | ||||||||
| William Ho | 481,000 | 0 | 0 | 1,603,438 | 221,260 | 0 | 7,322 | 2,313,020 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Brian Wong | $6,979,539 | $6,591,617 | — | +387,922 |
| Rodney Young | 2,691,496 | 2,175,226 | — | +516,270 |
| William Ho | 2,313,020 | 1,903,926 | — | +409,094 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Wong | RSU | 146,875 | — | $54,554 |
| Brian Wong | RSU | 60,000 | — | 22,286 |
| William Ho | RSU | 40,104 | — | 14,896 |
| William Ho | RSU | 20,000 | — | 7,429 |
| Brian Wong | RSU | 218,750 | — | 81,250 |
| Brian Wong | RSU | 119,791 | — | 44,494 |
| Brian Wong | RSU | 83,333 | — | 30,952 |
| Rodney Young | RSU | 58,750 | — | 21,823 |
| William Ho | RSU | 53,854 | — | 20,003 |
| Rodney Young | RSU | 47,395 | — | 17,605 |
| Rodney Young | RSU | 32,583 | — | 12,103 |
| William Ho | RSU | 26,833 | — | 9,967 |
| Rodney Young | RSU | 20,635 | — | 7,665 |
| William Ho | RSU | 7,807 | — | 2,900 |
| Brian Wong | RSU | 63,020 | — | 23,407 |
| Rodney Young | RSU | 140,000 | — | 52,003 |
| William Ho | RSU | 17,187 | — | 6,384 |
We have a pay-for-performance focused executive compensation philosophy. We believe that compensation should be designed to drive company performance aimed at increasing stockholder value. We seek to achieve this by using different elements of compensation and a market-based approach to attract, retain and motivate a high-performing team of executive officers and by aligning most of the compensation of each of our executives with the Company's short- and long-term performance, as well as each such executive's individual contributions.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc/Radford |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-29 | 76,867,722 | 23,639,125 | 55,527 | 76.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-29 | 76.48%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William RieflinIndependent · Departed during FY | $90,000 | $0 | $142,419 | — | $0 | $232,419 |
| Mary Ann GrayIndependent · Audit (Chair) | 65,000 | 0 | 142,419 | — | 0 | 207,419 |
| Michael GiordanoIndependent · Compensation (Chair) · Nominating/Governance | 59,000 | 0 | 142,419 | — | 0 | 201,419 |
| Wendye RobbinsIndependent · Audit · Not standing for re-election | 52,500 | 0 | 142,419 | — | 0 | 194,919 |
| Lori Lyons-WilliamsIndependent · Board Chair · Compensation · Nominating/Governance | 51,875 | 0 | 142,419 | — | 0 | 194,294 |
| Linda KozickIndependent · Audit · Nominating/Governance (Chair) | 49,500 | 0 | 142,419 | — | 0 | 191,919 |
| Brian WongEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $367,875 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $367,875 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rapt Therapeutics | 2024 | Brian Wong | $630,000 | $0 | $5,927,297 | $416,000 | $6,979,539 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Brian Wong | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Summary Compensation Table”. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 2 | Section 01, Rodney Young | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Summary Compensation Table”. As printed: 2,691,496. Filing ↗machine: r6 · c23 · span 849443–849452 |
| 3 | Section 01, William Ho | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Summary Compensation Table”. As printed: 2,313,020. Filing ↗machine: r4 · c23 · span 833172–833181 |
| 4 | Section 08, William Rieflin | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 232,419. Filing ↗machine: t21 · r2 · c15 · span 1108791–1108798 |
| 5 | Section 08, Mary Ann Gray | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 207,419. Filing ↗machine: t21 · r4 · c15 · span 1119116–1119123 |
| 6 | Section 08, Michael Giordano | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 201,419. Filing ↗machine: t21 · r3 · c15 · span 1113953–1113960 |
| 7 | Section 08, Wendye Robbins | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 194,919. Filing ↗machine: t21 · r6 · c15 · span 1129431–1129438 |
| 8 | Section 08, Lori Lyons-Williams | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 194,294. Filing ↗machine: t21 · r7 · c15 · span 1134590–1134597 |
| 9 | Section 08, Linda Kozick | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 191,919. Filing ↗machine: t21 · r5 · c15 · span 1124268–1124275 |
| 10 | Section 08, Brian Wong | DEF 14A | 2025-04-14 | 0000950170-25-053517 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2025 vote | Form 8-K | 2025-05-29 | 0000950170-25-079023 | Item 5.07 · say-on-pay result. As reported: 76.48% (votes for as printed: 76,867,722). Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 367,875 + equity 0 + all other 0 = 367,875, summed across the director compensation table rows.machine: formula: Σ = 367,875 |
| 14 | Rapt Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |